Compare AbCellera Biologics Inc (ABCL) vs Dominion Energy Inc (D) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Dominion Energy Inc — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Dominion Energy Inc trades at $69.92 (market cap $60.92B). The key difference: Dominion Energy Inc is far larger — about 25.9× AbCellera Biologics Inc's market cap, and Dominion Energy Inc pays a 3.86% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | D | |
|---|---|---|
Market Cap | $2.35B | $60.92B |
Sector | Health | Utilities |
52-Week High | $8.12 | $69.84 |
52-Week Low | $2.78 | $56.32 |
Enterprise Value | $1.99B | $113.32B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Dominion Energy (D) trades at $69.84, up 0.13% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 16.93% net income margin and trades near the analyst consensus price target of $69.50. Recent news highlights a proposed $66.8 billion acquisition by NextEra Energy, positioning Dominion as a key player in AI infrastructure and data center power demand.
The outlook remains positive due to strategic positioning in renewable energy and data center growth, though regulatory approval risks for the merger and high debt levels pose challenges. Earnings momentum and institutional support provide upside potential, but investors should monitor merger developments and interest rate impacts on utility valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →
